OncoMatch/Clinical Trials/NCT07108309
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Is NCT07108309 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BCD-236 and Chemotherapy for triple negative breast cancer.
Treatment: BCD-236 · Chemotherapy — To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression 0-2 points or <1% (0-2 points or <1%)
ER 0-2 points, PR 0-2 points or ER <1%, PR <1% (ASCO/CAP)
Required: PR (PGR) expression 0-2 points or <1% (0-2 points or <1%)
ER 0-2 points, PR 0-2 points or ER <1%, PR <1% (ASCO/CAP)
Required: HER2 (ERBB2) expression ≤1+ or 2+ without amplification (≤1+ or 2+ without amplification)
HER2 (≤1+) or HER2 (2+) in the absence of amplification of the Her-2-neu gene by ISH
Required: AXL expression (confirmed by immunohistochemistry)
Confirmed AXL expression in tumor cells according to immunohistochemistry
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy — locally advanced unresectable or metastatic TNBC
TNBC is progressive or relapsing on or after systemic therapy. The subject received at least 1 line of systemic therapy for locally advanced unresectable or metastatic TNBC, or she experienced a relapse / progressive disease during or within 6 months after completion of post-operative (adjuvant) chemotherapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07108309 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require ESR1?
Yes, ESR1 expression 0-2 points or <1% is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR expression 0-2 points or <1% is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 expression ≤1+ or 2+ without amplification is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify